Abstract
Targeted immunotherapy represents a significant advancement in the treatment of cancer, harnessing the body's immune system to selectively target and destroy cancer cells. Unlike traditional cancer treatments such as chemotherapy and radiation, which can affect both cancerous and healthy cells, targeted immunotherapies aim to focus on specific molecules or pathways involved in the tumor's growth and immune evasion. This article provides an overview of the latest advances in targeted immunotherapies, including monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and adoptive T cell therapies. We also discuss the challenges, opportunities, and future directions in the development of these therapies for personalized cancer treatment.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.